Pediatric
Efferon NEO
The first CE‑marked single-use multimodal extracorporeal blood purification device ever purpose‑built to treat pediatric sepsis and septic shock.
In the LASSO NEO study, hemoadsorption therapy with Efferon NEO was associated with faster resolution of multiple organ dysfunction and improved hemodynamic stabilization in pediatric sepsis patients. Treatment led to earlier discontinuation of vasopressor support and mechanical ventilation, reduced inflammatory burden, and a significantly shorter duration of intensive care support compared to standard therapy alone.
Specifications
- Polymeric adsorbent
- Macroporous hypercrosslinked styrene-divinylbenzene copolymer with immobilized selective ligand, suspension in saline
- Inner volume
- 60 ml
- Blood filling volume
- 30 ml
- Recommended blood flow rate through the device
- 3–7 mL/min per kg of body weight of the patient
- Construction
- Symmetrical polycarbonate cylinder with two end filters, O-rings and side covers with screw caps
- Weight
- 130 g
- Diameter × length
- 51 × 134 mm
- Individual packing
- PE / PA bag
- Sterilization
- radiation sterilization
Intended use
The device is intended for extracorporeal blood purification via an extracorporeal circuit. It can be performed as isolated hemoadsorption mode or in combination with RRT, ECMO and CPB. Inflammatory mediators and endotoxin are removed from patients' circulation. Timely administration improves vital functions and hinders progression of multiple organ failure in sepsis patients.
Instruction for use
Full instruction for use covering preparation, priming, perfusion and disposal protocols.
PDF will be available soon.